NEUROCRINE BIOSCIENCES INC Sale Leaseback Transaction, Current Period Gain Recognized
NEUROCRINE BIOSCIENCES INC (NBIX) reported Sale Leaseback Transaction, Current Period Gain Recognized of $700.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-08.
Discontinued › Income Statement › Other Income
us-gaap:SaleLeasebackTransactionCurrentPeriodGainRecognized · last filed 2019-02-08
- NEUROCRINE BIOSCIENCES INC sale leaseback transaction, current period gain recognized for the quarter ending 2018-12-31 was $200.00K, a 0.00% change year-over-year.
- NEUROCRINE BIOSCIENCES INC sale leaseback transaction, current period gain recognized for the quarter ending 2018-09-30 was $100.00K, a 50.00% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC sale leaseback transaction, current period gain recognized for the quarter ending 2018-06-30 was $200.00K, a 77.78% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC sale leaseback transaction, current period gain recognized for the quarter ending 2018-03-31 was $200.00K, a 77.78% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC sale leaseback transaction, current period gain recognized for fiscal 2018 was $700.00K, a 66.67% decline from fiscal 2017.
- NEUROCRINE BIOSCIENCES INC sale leaseback transaction, current period gain recognized for fiscal 2017 was $2.10M, a 38.24% decline from fiscal 2016.
- NEUROCRINE BIOSCIENCES INC sale leaseback transaction, current period gain recognized for fiscal 2016 was $3.40M, a 3.03% increase from fiscal 2015.
- NEUROCRINE BIOSCIENCES INC sale leaseback transaction, current period gain recognized for fiscal 2015 was $3.30M, a 3.13% increase from fiscal 2014.
| Period end | Sale Leaseback Transaction, Current Period Gain Recognized 3 month | Sale Leaseback Transaction, Current Period Gain Recognized 6 month | Sale Leaseback Transaction, Current Period Gain Recognized 9 month | Sale Leaseback Transaction, Current Period Gain Recognized 9 month as first filed | Sale Leaseback Transaction, Current Period Gain Recognized 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $300.00K derived: sum of 2 quarters · filed 2019-02-08 | $500.00K derived: sum of 3 quarters · filed 2019-02-08 | $700.00K 10-K · filed 2019-02-08 | |
| 2018-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $300.00K derived: sum of 2 quarters · filed 2018-11-05 | $500.00K 10-Q · filed 2018-11-05 | $700.00K derived: sum of 4 quarters · filed 2019-02-08 | |
| 2018-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $400.00K 10-Q · filed 2018-07-31 | $600.00K derived: sum of 3 quarters · filed 2019-02-08 | $800.00K derived: sum of 4 quarters · filed 2019-02-08 | |
| 2018-03-31 | $200.00K 10-Q · filed 2018-04-30 | $400.00K derived: sum of 2 quarters · filed 2019-02-08 | $600.00K derived: sum of 3 quarters · filed 2019-02-08 | $1.50M derived: sum of 4 quarters · filed 2019-02-08 | |
| 2017-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $400.00K derived: sum of 2 quarters · filed 2019-02-08 | $1.30M derived: sum of 3 quarters · filed 2019-02-08 | $2.10M 10-K · filed 2019-02-08 | |
| 2017-09-30 | $200.00K 10-Q · filed 2017-11-01 | $1.10M derived: sum of 2 quarters · filed 2017-11-01 | $1.90M 10-Q · filed 2018-11-05 | $2.00M 10-Q · filed 2017-11-01 | $2.80M derived: sum of 4 quarters · filed 2019-02-08 |
| 2017-06-30 | $900.00K 10-Q · filed 2017-08-03 | $1.80M 10-Q · filed 2018-07-31 | $2.60M derived: sum of 3 quarters · filed 2019-02-08 | $3.50M derived: sum of 4 quarters · filed 2019-02-08 | |
| 2017-03-31 | $900.00K 10-Q · filed 2018-04-30 | $1.70M derived: sum of 2 quarters · filed 2019-02-08 | $2.60M derived: sum of 3 quarters · filed 2019-02-08 | $3.50M derived: sum of 4 quarters · filed 2019-02-08 | |
| 2016-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08 | $1.70M derived: sum of 2 quarters · filed 2019-02-08 | $2.60M derived: sum of 3 quarters · filed 2019-02-08 | $3.40M 10-K · filed 2019-02-08 | |
| 2016-09-30 | $900.00K 10-Q · filed 2017-11-01 | $1.80M derived: sum of 2 quarters · filed 2017-11-01 | $2.60M 10-Q · filed 2017-11-01 | $3.50M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-06-30 | $900.00K 10-Q · filed 2017-08-03 | $1.70M 10-Q · filed 2017-08-03 | $2.60M derived: sum of 3 quarters · filed 2018-02-13 | $3.40M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2016-03-31 | $900.00K 10-Q · filed 2017-05-09 | $1.70M derived: sum of 2 quarters · filed 2018-02-13 | $2.50M derived: sum of 3 quarters · filed 2018-02-13 | $3.30M derived: sum of 4 quarters · filed 2018-02-13 | |
| 2015-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $1.60M derived: sum of 2 quarters · filed 2018-02-13 | $2.40M derived: sum of 3 quarters · filed 2018-02-13 | $3.30M 10-K · filed 2018-02-13 | |
| 2015-09-30 | $800.00K 10-Q · filed 2016-11-02 | $1.60M derived: sum of 2 quarters · filed 2016-11-02 | $2.50M 10-Q · filed 2016-11-02 | $3.20M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2015-06-30 | $800.00K 10-Q · filed 2016-08-03 | $1.70M 10-Q · filed 2016-08-03 | $2.40M derived: sum of 3 quarters · filed 2017-02-14 | $3.20M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2015-03-31 | $800.00K 10-Q · filed 2016-05-05 | $1.60M derived: sum of 2 quarters · filed 2017-02-14 | $2.40M derived: sum of 3 quarters · filed 2017-02-14 | $3.20M derived: sum of 4 quarters · filed 2017-02-14 | |
| 2014-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $1.60M derived: sum of 2 quarters · filed 2017-02-14 | $2.40M derived: sum of 3 quarters · filed 2017-02-14 | $3.20M 10-K · filed 2017-02-14 | |
| 2014-09-30 | $800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $1.60M derived: sum of 2 quarters · filed 2015-10-29 | $2.40M 10-Q · filed 2015-10-29 | $3.20M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-29 | $1.60M 10-Q · filed 2015-07-29 | $2.40M derived: sum of 3 quarters · filed 2016-02-11 | $3.10M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-03-31 | $800.00K 10-Q · filed 2015-04-30 | $1.60M derived: sum of 2 quarters · filed 2016-02-11 | $2.30M derived: sum of 3 quarters · filed 2016-02-11 | $3.10M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2013-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $1.50M derived: sum of 2 quarters · filed 2016-02-11 | $2.30M derived: sum of 3 quarters · filed 2016-02-11 | $3.10M 10-K · filed 2016-02-11 | |
| 2013-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $1.50M derived: sum of 2 quarters · filed 2014-11-04 | $2.30M 10-Q · filed 2014-11-04 | ||
| 2013-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $1.60M 10-Q · filed 2014-08-06 | |||
| 2013-03-31 | $800.00K 10-Q · filed 2014-05-01 | ||||
| 2012-12-31 | $3.00M 10-K · filed 2015-02-09 | ||||
| 2011-12-31 | $3.00M 10-K · filed 2014-02-11 | ||||
| 2010-12-31 | $2.90M 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |